Humana and UnitedHealthcare Expand Medicare Advantage Coverage for Lifeward Exoskeleton

Lifeward Ltd., a medical technology company specializing in personal exoskeletons, has received prior authorization from Humana's Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. This follows an earlier authorization granted by UnitedHealthcare, marking two of the largest Medicare Advantage providers endorsing reimbursement coverage for this technology. Together, these two insurers cover approximately 47% of all Medicare Advantage enrollees, significantly expanding access to advanced mobility solutions for individuals with spinal cord injuries. The prior authorization approval by Humana is seen as a milestone in the growing acceptance of personal exoskeletons within the U.S. healthcare reimbursement landscape. It provides beneficiaries with a more predictable and reliable pathway to access these devices, which are designed to improve mobility and quality of life. This development aligns with the broader trend of innovative medical technologies gaining traction among payers aiming to enhance patient care options. Since the Centers for Medicare & Medicaid Services (CMS) established a formal reimbursement pathway for personal exoskeletons in 2024, Lifeward has steadily increased its submission of claims through both traditional Medicare and Medicare Advantage Plans. The expanding payer adoption has led to accelerated prior authorization approvals, which in turn has strengthened Lifeward's revenue and cash flow projections, supporting scalable growth within the U.S. market. Lifeward’s portfolio includes several rehabilitation and recovery-focused technologies, such as the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. The company operates internationally but demonstrates a significant commitment to expanding its footprint in the U.S. through partnerships with major Medicare Advantage providers. This strategic expansion plays a key role in facilitating access to advanced assistive technology for Medicare beneficiaries with physical disabilities. Overall, the inclusion of ReWalk 7 within Medicare Advantage reimbursement plans underscores a shift toward integrating innovative mobility solutions into standard care frameworks. It reflects increasing payer recognition of the clinical value and potential health benefits personal exoskeletons offer to individuals living with spinal cord injuries. This regulatory and market progress positions Lifeward favorably as the exoskeleton market continues to evolve in the healthcare industry.